Search academic texts

Information × Registration Number 0220U000678, 0117U006446 , R & D reports Title Efficacy, cardio- and gastrointestinal safety of immunosuppressants and calcium antagonists of the dihydropyridine series when combined in a model of rheumatoid arthritis combined with arterial hypertension popup.stage_title Head Seredinskaya Nataliya Nikolaevna, Доктор медичних наук Registration Date 02-11-2020 Organization State Institution "Institute of Pharmacology and Toxicology of National Academy of Medical Sciences of Ukraine" popup.description2 Possibilities and feasibility of combined use of immunosuppressants of synthetic origin (on the example of Leflunomide) and biological origin (on the example of the genetically modified drug Enbrel) with the calcium antagonist of the dihydropyridine series by amytodenitis, combined with atherotic pathogenes The result of the study of the analgesic effect of Leflunomide testifies to its effectiveness against the background of comorbid pathology. Amlodipine enhances analgesic activity when combined with Leflunomide, which justifies the use of a calcium antagonist to enhance the analgesic effect of Leflunomide when required as its primary indication (as an antihypertensive agent). Independent administration of Leflunomide does not lead to the manifestation of an anti-edematous effect on the background of combined pathology, while Amlodipine promotes the manifestation of an anti-edema effect of Leflunomide when combined. Increased blood pressure and tachycardia with Leflunomide require the combined use of an immunosuppressant and appropriate cardiac (in particular, hypotensive and antiarrhythmic) therapies. The lack of a hypertensive effect in Enbrel indicates the inappropriateness of the combined use of Amlodipine with Enbrel in order to reduce blood pressure amid joint pathology. The results obtained prove the feasibility of monitoring the frequency and rhythm of heart rate for the use, including combination, of investigational therapies against the background of a comorbid condition. The use of Leflunomide, Enbrel and Amlodipine does not normalize but worsens the gastro- and enteropathic conditions. The least vulnerable is Enbrel's self-administration and combined administration of Leflunomide with Amlodipine on the background of associated pathology. These results make it possible to optimize the ways of choice of medicines of these pharmacotherapeutic groups and to improve the medical technology of treatment of comorbid conditions, in particular - arterial hypertension accompanying or arising on rheumatoid arthritis. Product Description popup.authors Акімова Н. В. Бершова Т. А. Киричок Л. М. Марченко О. М. Матвієнко А. В. Мохорт Н. А. Серединська Н. М. Суворова О. С. Хоменко В. С. popup.nrat_date 2021-03-17 Close